CC-90001 was nominated by reviewer Christian Kuttruff . CC-90001 is a JNK (c-Jun N-Terminal Kinase) inhibitor and a Phase II clinical candidate for idiopathic pulmonary fibrosis ( NCT03142191). Christian says, “Preclinical evidence suggests that c-Jun N-terminal kinase (JNK) enzyme function is required for [...]
1 minute read
Jan. 17, 2022
CC-90001: a JNK Inhibitor for Pulmonary Fibrosis
CC-90001
oral JNK2 kinase inhibitor Ph. II candidate for pulmonary fibrosis from HTS and SBDD Journal of Medicinal Chemistry Celgene (Bristol Myers Squibb), San Diego, CA
Reviewer: